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Introduction: The clinical efficacy of specific interleukin-6 inhibitors has confirmed the central role of IL6 in rheumatoid
arthritis (RA). However the local role of IL6, in particular in synovial fibroblasts (SF) as a direct cellular target to IL6/sIL6R
signal is not well characterized. The purpose of the study was to characterize the crosstalk between TNFα and IL6/sIL6R
signaling to the effector pro-inflammatory response of SF.
Methods: SF lines were stimulated with either TNFα, IL6/sIL6R, or both together, for the time and dose indicated for each
experiment, and where indicated, cells were treated with inhibitors actinomycin D, adalimumab, ruxolitinib and cycloheximide.
mRNA expression of cytokines, chemokines and matrix metalloproteases (MMPs) were analyzed by quantitative RT-PCR. Level
of IL8/CXCL8 and CCL8 in culture supernatants was measured by ELISA. Mononuclear and polymorphonuclear cells migration
assays were assessed by transwell using conditioned medium from SF cultures. Statistical analyses were performed as indicated
in the corresponding figure legends and a p-value < 0.05 was considered statistically significant.
Results: The stimulation of SF with IL6/sIL6R and TNFα, cooperatively promotes the expression of mono- and lymphocytic
chemokines such as IL6, CCL8 and CCL2, as well as matrix degrading enzymes such as MMP1, while inhibiting the induction of
central neutrophil chemokines such as IL8/CXCL8. These changes in the pattern of chemokines expression resulted in reduced
polymorphonuclear (PMN) and increased mononuclear cells (MNC) chemoattraction by SF. Mechanistic analyses of the
temporal expression of genes demonstrated that the cooperative regulation mediated by these two factors is mostly induced
through de novo transcriptional mechanisms activated by IL6/sIL6R. Furthermore, we also demonstrate that TNFα and IL6/sIL6R
cooperation is partially mediated by the expression of secondary factors signaling through JAK/STAT pathways.
Conclusions: These results point out to a highly orchestrated response to IL6 in TNFα-induced SF and provide additional
insights into the role of IL6/sIL6R in the context of RA, highlighting the contribution of IL6/sIL6R to the interplay of SF with
other inflammatory cells.
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Interleukin-6 (IL6) is a pleiotropic cytokine with either pro-
or anti-inflammatory effects depending on the cellular con-
text and the pathophysiological state. IL6 plays a central role
in local and systemic manifestations of RA and represents a
successful therapeutic target [1, 2]. Stromal and immune
cells produce IL6 upon induction with major inflammatory
activators such as tumour necrosis factor α (TNFα) or Inter-
leukin 1-beta (IL1β). Normal physiological concentrations
of IL6 in human serum are relatively low, but rapidly
increase under pathological conditions [3, 4]. Synovial fibro-
blasts (SF) of the lining are the primary source of IL6
mRNA and protein in the synovium of RA patients [5].
Central to the IL6 context dependent function is the
receptor system gp130/IL6R. In contrast to the ubiqui-
tously expressed subunit gp130, the membrane subunit
IL6R is mostly restricted to hepatocytes, myeloid cells
and some lymphocytes. In contrast resident cells, includ-
ing fibroblasts, can only respond to IL6 through trans-
signaling mediated by soluble IL6 receptor (sIL6R) [6, 7].
While both pro- and anti-inflammatory effects have been
associated to signal activation of the fully-competent re-
ceptor gp130/IL6R, signaling mediated through gp130/
sIL6R has been mostly linked to the induction of pro-
inflammatory programs [8]. Interestingly, in the context
of inflammatory arthritis, increased synovial sIL6R levels
correlate with enhanced joint destruction and leukocyte
recruitment [3, 7, 9], but the role of the IL6/sIL6R trans-
signaling on inflamed synovial tissue is poorly known.
SF are essential players in RA pathophysiology, under-
going significant hyperplasia in rheumatoid arthritis
(RA) and responding to exogenous proinflammatory
stimuli, particularly to TNFα, by producing a large var-
iety of proinflammatory, bone destructive and cartilage-
destructive mediators [10] thus contributing to perpetu-
ate the inflammatory milieu in the joint. Interestingly, a
recent investigation has demonstrated the cooperative
role of TNFα and IL6/sIL6R in regulating the cell cycle
and viability of synovial fibroblasts cells, accelerating
RASF proliferation [11], suggesting that the crosstalk be-
tween these two factors may enhance the pathological
impact of SF cells in RA.
The hierarchy of TNFα in SF inflammatory activity
has been intensively studied in the last decades [12, 13].
SF have a central role in the recruitment and retention
of leukocytes in the inflamed joint [14–16] as well as in
many other effector mechanisms resulting in chronic in-
flammation and joint destruction [10].
The clinical efficacy of both TNFα and IL6 antagonists has
been extensively demonstrated in RA patients [17]. However,
although many efforts have focused in understanding the
specific pathogenic role of IL6 in adaptive immunity in arth-
ritis, much less is known about the direct effects of IL6
trans-signaling on the synovial inflammatory process.In this study, we show that IL6 trans-signaling induces
an inflammatory response in SF that modulates the ro-
bust TNFα-induced inflammatory signal, by regulating
the cytokine and chemokine expression pattern. Further-
more, although IL6/sIL6R has a limited impact on the
expression of matrix degrading enzymes, it regulates the
expression profile of specific matrix metalloproteases in-
duced by TNFα. Our results point out to a highly or-
chestrated response to these key cytokines on the SF
effect or response in RA.
Methods
Patients and cells
SF cultures were established by explant growth of synovial
tissues obtained by arthroscopic knee biopsies from pa-
tients without previous joint disease at elective arthroscopy
for minor traumatic lesions, or patients with RA at the time
of prosthetic replacement surgery. Patients signed a written
informed consent, and the study was approved by the Eth-
ics Committee of Hospital 12 de Octubre, Madrid, Spain
(N° CEI:17/085). All methods involving humans were per-
formed in accordance with the relevant guidelines and reg-
ulations. SF were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% heat inactivated
fetal bovine serum (FBS) (Lonza, Verviers, Belgium) and
used after 3rd passage. For all tests SF lines were stimulated
with either TNFα, IL6/sIL6R, or both together in DMEM
0.5% FBS, the time and dose of the treatment will be indi-
cated for each experiment. TNFα, IL6 and sIL6R (Prepro-
Tech, Rocky Hill, NJ, USA) were reconstituted according to
manufacturer instructions. Where indicated, cells were
treated with inhibitors Actinomycin D (10 μg/ml) (Sigma-
Aldrich Quimica SA, Madrid, Spain), Adalimumab (10 μM)
(AbbVie, North Chicago, IL, USA), Ruxolitinib (1 μM) (Sell-
eckchem, Houston, TX, USA) and Cycloheximide (5 μM)
(Sigma-Aldrich Quimica SA).
mRNA analysis
First-strand cDNA synthesis was performed using 2 μg of
total RNA with High-Capacity cDNA Reverse Transcrip-
tion kit (Applied Biosystems, Foster City, CA, USA) ac-
cording to manufacturer protocol. Samples were analyzed
by quantitative RT-PCR (RT-qPCR) with gene-specific
primer pairs (Additional file 1: Table S1) on an Applied
Biosystem 7500 Fast Real-Time PCR System (Applied Bio-
system) using Power Sybr Green PCR Master Mix (Ap-
plied Biosystems). Values were normalized to those of the
endogenous reference (HPRT1 gene) using the 2-ΔΔCt
method. In each case, multiple reactions were performed
using 4–6 independent biological replicates.
Enzyme-linked immunosorbent assay (ELISA)
Concentrations of IL8/CXCL8 and CCL8 in culture su-
pernatants were determined by ELISA (Biolegend Inc.,
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protocols. The read-out for all ELISAs was carried out
with a MultiskanEX plate reader (ThermoScientific).
Cell migration assay
Mononuclear and polymorphonuclear leukocytes were
obtained from peripheral blood from healthy donors (n =
7) by density gradient centrifugation using Lympholyte-
poly (Cederlane Laboratories, Burlington, Canada). Cell
migration was assessed using 6.5mm Transwell with
5.0 μm pore polycarbonate membrane insert (Corning
Inc., Corning, NY, USA). 0.3 × 106 cells in DMEM 0.5%
FBS were seeded in the upper chamber of the transwell. In
the lower chamber we added conditioned medium from
SF cultures (n = 4) stimulated for 48 h with either TNFα
(10 ng/ml) or IL6 and sIL6R (50 ng/ml each). After an in-
cubation for 4 h, migrated cells from the lower chamber
were collected and analyzed by flow cytometry with a BD
FACSCalibur instrument (Becton Dickinson, San José,
CA, USA). Subpopulations of polymorphonuclear (PMN)
and mononuclear cells (MNC) were identified by forward
and side scatter. By combining donors and SF cultures, a
total of 19 experiments were performed.
Statistical analysis
Data were analyzed using GraphPad Prism software v6.0
(GraphPad Software, San Diego, CA, USA). Statistical ana-
lyses were performed as indicated in the corresponding fig-
ure legends. A p-value < 0.05 was considered statistically
significant (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
Results
Comparative analysis of genes regulated by TNFα or IL6/
sIL6R signaling in SF
To investigate the relative contribution of IL6 to the SF in-
flammatory response, we analyzed the expression pattern
of a large group of cytokines, chemokines and matrix
metalloproteases (MMPs) with important roles in RA
pathophysiology. We first confirmed the lack of effect of
IL6 alone compared to IL6/sIL6R or TNFα on the expres-
sion of known target genes such as CCL2 and IL6 (data
not shown) in cultured SF. Furthermore, despite individ-
ual baseline differences on gene expression, both RA and
non-RA cultured SF respond similarly to TNFα and/or
IL6/sIL6R stimulation (data not shown) and therefore, SF
from both healthy and RA donors were indistinctly used.
In dose-response experiments, RT-qPCR analyses showed
that TNFα induced the expression of the cytokine IL6, che-
mokines genes IL8/CXCL8, CCL2, CCL5 and CCL8, and
MMPs genes MMP1, MMP3 and MMP10 (Fig. 1a). IL6/
sIL6R induced the expression of IL6 itself, mononuclear-
cells recruiting chemokines such as CCL2 or CCL8 but no
the neutrophil-recruiting chemokine gene IL8/CXCL8 and
in contrast to the robust activation of MMPs mediated byTNFα, only MMP1 was partially expressed upon stimulation
by IL6/sIL6R trans-signaling at the higher dose tested (Fig.
1b). The magnitude of gene inductions by IL6/sIL6R was 2–
100 times lower than by TNFα.
Overall, IL6 trans-signaling mediates effects partially
overlapping to those of TNFα in SF, supporting the co-
ordinated expression of cytokines, chemokines and
matrix metalloproteases central to RA pathophysiology.
IL6/sIL6R trans-signal modulates the TNFα-induced
inflammatory response of SF
To investigate IL6 trans-signaling regulation of the inflam-
matory response in SF, we stimulated SF cultures with dif-
ferent suboptimal doses of TNFα plus a fixed dose of IL6
and sIL6R (50 ng/ml) according to dose-response assays of
representative genes regulated by each factor (Fig. 1). Co-
operative stimulation of SF with both TNFα and IL6/sIL6R
enhanced the expression of a common regulated gene such
as IL6 (Fig. 2a). Although the observed increased expression
of CCL8 and MMP1 was not statistically significant (p =
0.25 and p = 0.43 respectively, at the higher dose of TNFα),
further mRNA and protein expression analysis along the
present study demonstrated the consistency of the increase
shown for those genes. In contrast, MMP3, a gene specific-
ally activated by TNFα but not IL6/sIL6R, was not affected
by IL6 trans-signaling (Fig. 2a). IL6 has been shown to
regulate the expression pattern of chemokines on stromal
cells to drive the transition from the recruitment of neutro-
phils to mononuclear cells [12]. Consistently, TNFα-
induced mRNA and protein expression of the neutrophil-
recruiting chemokine IL8/CXCL8 was partially inhibited by
the trans-signal activation of IL6/sIL6R in SF, whereas
TNFα and IL6/sIL6R cooperated to up-regulate the protein
expression of mononuclear leukocytes chemoattractant
chemokine CCL8 (Fig. 2a and b). Interestingly, IL6/sIL6R
also inhibited the TNFα-induced expression of MMP10, an
enzyme linked to the resolution of inflammation by macro-
phages [18] (Fig. 2a).
To analyze the functional implications of the switch in
the pattern of chemokines after the cooperative stimulation
with TNFα and IL6/sIL6R, we performed a cell migration
experiment using conditioned media from SF cultures as
chemoattractant for leukocytes. Conditioned media from
SF cultures treated with both TNFα and IL6/sIL6R reduced
significantly the percentage of polymorphonuclear (PMN)
cells in comparison with medium from TNFα-stimulated
cultures (Fig. 2c). Likewise, TNFα plus IL6/sIL6R condi-
tioned media induced a significant increase in the recruit-
ment of mononuclear cells (MNC) (Fig. 2c).
IL6/sIL6R regulates the kinetics of the TNFα-inflammatory
response
Expression of genes activated by continuous exposure to
TNFα is determined by transcriptional and post-
Fig. 1 Dose-response expression of genes in SF. SF were stimulated for 24 h with increasing doses of either TNFα (a) or IL6/sIL6R (b). Graphics
show the changes in mRNA expression of indicated genes in relation to untreated control. Mean ± SEM from three to six SF lines (*Kruskal-Wallis
with Dunn’s multiple comparisons test)
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kinetics [19–21]. To distinguish the potential regula-
tion of these mechanisms upon induction with IL6/
sIL6R, we first set the temporal pattern of induction
for analyzed genes.
The kinetics of genes stimulated by TNFα in SF mostly
fit into the three broad classes, as previously described in
other cell types [19] (Additional file 2: Figure S1a). Thus,
the expression of an early gene (IL6) was consistently de-
tected at 0.5 h upon induction, while intermediate genes
(CCL2, IL8/CXCL8) are observed before 2 h and late ex-
pression genes (CCL8, MMP1) later than 2 h. The expres-
sion of genes mediated by continuous exposure of IL6/
sIL6R fit into a similar pattern of induction, although
some of the genes that are common to both factors fall
into a different category. The induction of IL6 and MMP1
follows identical kinetics for both inflammatory factors. In
contrast, the expression of CCL8 or CCL2 induced by IL6/
sIL6R showed faster kinetics than that mediated by TNFα,
showing CCL2 a less stable induction (Additional file 2:
Figure S1b). These results more likely reflect differencesin the underlying regulatory mechanisms induced by ei-
ther inflammatory cytokine.
The expression kinetics of genes co-stimulated with
TNFα and IL6/sIL6R may provide information about the
molecular mechanisms operating in the cooperative induc-
tion of genes. For all TNFα-induced genes, kinetics was
maintained after co-stimulation with IL6/sIL6R, but differ-
ences were observed in the time of the cooperative effect
(Fig. 3). The increase of IL6 and the decrease of IL8/CXCL8
expression by IL6/sIL6R was detectable as soon as 30min
upon induction, more likely showing changes in transcrip-
tion and/or mRNA stability mechanisms. However, in-
creased expression of intermediate and late expression
genes such as CCL2, CCL8 or MMP1 occurs at later time,
suggesting that secondary factors may underlie the coopera-
tive expression of these genes (Fig. 3a). A similar pattern of
expression was obtained when we analyzed the protein re-
leased to the culture medium (Fig. 3b). Although not statis-
tically significant, a moderate IL8/CXCL8 inhibition was
detectable at 6 h after induction, while enhanced expression
of CCL8 was only detectable later at 24 h (Fig. 3b).
Fig. 2 Modulation of TNFα-induced genes by IL6/sIL6R in SF. a Change in mRNA expression upon stimulation with increasing doses of TNFα and a fix
dose of IL6/sIL6R (50 ng/ml each) in relation to untreated control. Mean ± SEM from three to eight SF lines (*Kruskal-Wallis with Dunn’s multiple
comparisons test; #Wilcoxon test). b Protein levels of CCL8 and IL8/CXCL8 upon induction with TNFα (10 ng/ml) and IL6/sIL6R (50 ng/ml each). Mean ±
SEM from seven SF lines (*Wilcoxon test). c Percentage of polymorphonuclear and mononuclear leukocytes in cell migration assays (n = 19) (*One-way
ANOVA with Tukey’s multiple comparison test)
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through de novo transcriptional mechanisms
Accumulation of mRNA may be influenced by ongoing
transcription or mRNA stability. To investigate the rela-
tive contribution of mRNA stability to the induction of
genes mediated by TNFα or IL6/sIL6R in SF, we measured
changes in mRNA expression over time after blocking
transcription with actinomycin D (ActD). We determined
mRNA expression after 24 h of induction with either
TNFα or IL6/sIL6R, relative to the baseline value before
the addition of ActD. Our results showed that all tested
genes stimulated by IL6/sIL6R responded similarly, with
half-lives of mRNA transcripts decay varying from 0.8 to
2 h (Fig. 4a). In contrast, mRNAs induced by TNFα were
on average more stable, lasting more than 2 h for mostgenes. The half-life of decay for IL6 mRNA stimulated by
TNFα was shorter than for the rest of the genes, but simi-
lar to that stimulated by IL6/sIL6R (0.8 to 2 h) (Fig. 4b).
We could not determine the half-life of decay for MMP3,
since we found no consistent decrease in stability up to 4
h after treatment with ActD. These results suggest that,
while both transcriptional and post-transcriptional mecha-
nisms are involved in the modulation of TNFα induced
genes, the short half-life of IL6/sIL6R induced mRNAs
may reflect a dominant role for de novo transcription. We
also observed that co-stimulation of SF with both TNFα
and IL6/sIL6R did not significantly modify the half-life of
analyzed genes (Fig. 4c), suggesting that regulation of the
mRNA stability of TNFα-induced genes is not affected by
the modulation after trans-signal activation of IL6/sIL6R.
Fig. 3 Kinetic patterns of cooperative gene expression in SF. SF were cultured in the presence or absence of TNFα (10 ng/ml), IL6/sIL6R (50 ng/ml each) or
both. a Representative genes IL6, CCL2, IL8/CXCL8, CCL8, and MMP1mRNA expression of four to six independent cultures. b IL8/CXCL8 and CCL8 protein in
supernatants of six independent SF cultures. Values are mean ± SEM (vs control, *2way ANOVA with Fisher’s LSD multiple comparisons test)
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TNFα exposure for longer than 24 h promotes the stability
of mRNA expression in fibroblasts by epigenetic mecha-
nisms, influencing the temporal order of induction of in-
flammatory genes [19, 21, 22]. To distinguish the potential
role of these priming mechanisms, we first examined gene
expression changes in response to TNFα withdrawal. We
cultured SF in the presence of TNFα for 24 h, removed
the inflammatory input by washing the cells, and added
new medium with adalimumab (ADA) to block residualTNFα and with IL6/sIL6R for additional 24 h (Fig. 5). SF
pre-exposed to TNFα and treated with ADA did not dis-
play enhanced induction of early (IL6, CCL2 and IL8/
CXCL8) nor late genes (MMP1 and MMP3) after IL6/
sIL6R treatment, showing expression levels similar to the
induced with only IL6/sIL6R (Fig. 5). We also observed
that mRNA expression of MMP3 was more resistant to
TNFα withdrawal probably due to its stability. These data
suggest that the observed cooperative effect requires con-
comitant induction by both TNFα and IL6/sIL6R.
Fig. 4 Stability of mRNA encoded by early and late genes. SF were stimulated for 24 h with either IL6/sIL6R (50 ng/ml each) (a), TNFα (10 ng/ml)
(b), or both (c). Change of IL6, CCL2, IL8/CXCL8, CCL8, MMP1 and MMP3 mRNA expression are relative to the baseline value before the addition of
actinomycin D (ActD) (0 h). Data are the mean of three independent experiments
Valin et al. BMC Molecular and Cell Biology           (2020) 21:74 Page 7 of 12These results collectively support the view that, although
regulation of the mRNA stability and priming mechanisms
may determine the kinetics of TNFα-induced gene expres-
sion, cooperative induction by TNFα and IL6/sIL6R is
more likely mediated through coordinated de novo tran-
scriptional mechanisms.
Late crosstalk between TNFα and IL6/sIL6R is mediated
by activation of the JAK-STAT pathway
The delayed effect on the cooperative expression of genes
such as CCL8, CCL2 or MMP1 (Fig. 3a) suggested that ei-
ther TNFα or IL6/sIL6R induces secondary mechanisms
dependent of new protein synthesis. This hypothesis was
tested by inhibiting the protein synthesis with cyclohexi-
mide (CHX). CHX inhibited the expression of late genes
such as CCL8 and MMP1 induced by either TNFα (Add-
itional file 3: Figure S2a) or IL6/sIL6R (Additional file 3:
Figure S2b), suggesting that protein-synthesis-dependent
pathways are partly involved in the expression of these
genes in SF, in contrast to early or intermediate genes
such as IL6, IL8/CXCL8 and CCL2.
Previous investigations have demonstrated that TNFα
stimulation of SF induces the expression of several lympho-
cyte-attracting chemokines through a JAK signaling-
mediated mechanism, dependent on autocrine release of
type I Interferons (IFN) [23]. To confirm this possibility inour model, we analyzed the RSAD2 mRNA expression, a
classical IFN-induced gene, after TNFα treatment. We ob-
served a high induction of RSAD2 that was completely
inhibited in the presence of the JAK/STAT inhibitor ruxoli-
tinib (RUXO) (Fig. 6a). As expected, induction of IL6/sIL6R
dependent genes was abrogated by RUXO treatment (Fig.
6b). Further analyses demonstrated that RUXO significantly
inhibited TNFα-induced expression of CCL2 and CCL8, im-
plying that the secondary mediator acts through JAK/STAT.
Interestingly, MMP1, other late gene regulated by CHX was
not affected by RUXO, suggesting that a JAK/STAT-inde-
pendent but protein-synthesis-dependent pathways is partly
involved inMMP1 expression.
These experiments further revealed that a TNFα-
induced autocrine mechanism is regulating part of the
TNFα expression program in SF. This autocrine mech-
anism induced by TNFα shares a common JAK/STAT
signaling pathway with IL6/sIL6R that may partially ac-
count for the cooperative expression of specific genes.
Discussion
The response of resident cells in the synovium is essen-
tial to RA pathogenesis and it is conditioned by inflam-
matory cytokines. Although, the function of the two
pivotal cytokines, TNFα and IL6, has been extensively
studied in this context, most investigations have focused
Fig. 5 Effect of adalimumab on TNFα-induced genes modulated by
IL6/sIL6R. a Schematic representation of the experiment. SF were
stimulated with TNFα (10 ng/ml) for 24 h. Inflammatory input was
removed by washing cells and the second stimuli IL6/sIL6R (50 ng/
ml each) was added in the presence of adalimumab (ADA) (10 μg/
ml) to block any residual TNFα. b Graphics show the change on the
mRNA expression of representative genes. Untreated SF was used as
reference. Data are mean ± SEM of three independent experiments
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expression. Our present work shows that IL6/sIL6R signal-
ing is able to modulate the TNFα inflammatory response
elicited in SF, promoting changes of the inflammatory gene
expression pattern associated to RA pathogenesis. Further-
more, we provide insight into the molecular mechanisms
that regulate the crosstalk between both cytokines.
The mode of action of IL6 is contextual, defined by
other factors present within the local milieu [10]. Al-
though IL6 is defined as an inflammatory cytokine, it does
not directly induce leukocyte recruitment [15]. Rather,
previous studies have shown the ability of IL6, either aloneor cooperating with other factors, to modify inflammatory
infiltrates [24–28]. Analysis of adjuvant-induced arthriti-
s(AIA) in IL6+/+ and IL6−/− mice demonstrated that IL6
deficiency is associated with reduced synovial infiltration
and is accompanied by a defect in both CCL2 expression
and the recruitment of leukocytes bearing the CCL2 re-
ceptor CCR2 [6]. Our results show that the induction of
IL6/sIL6R signaling in SF mainly stimulates the expression
of cytokines and chemokines that attract lymphocyte and
monocyte cells, although at a lower level than TNFα.
However, the cooperative activation of both factors further
enhances the expression of common chemokines and cy-
tokines, thus potentially contributing to sustain the
leukocyte influx into the synovial tissue. The impact of
IL6/sIL6R and TNFα combination in SF may be more
relevant in the context of RA where the local increase of
sIL6R correlates with the extent of leukocyte infiltration
and joint destruction [3, 9]. Because the expression of
IL6R within the RA synovial environment is mainly re-
stricted to leukocytes [29], infiltrating cells may be the
source of the synovial sIL6R in response to inflammatory
mediators such as TNFα [26, 30–32]. The sIL6R would
then be acting as a paracrine mediator on synovial cells,
further inducing leukocyte recruitment during inflamma-
tion [33]. Several studies have highlighted a role for sIL6R
in regulating the expression of chemokines and adhesion
molecules [8, 31, 32, 34–37], thus mediating the transition
between the early neutrophilic stage of acute inflamma-
tion and the more sustained mononuclear cell influx [26].
Interestingly, mouse models of IL6−/− showed reduced
neutrophil accumulation at sites of infection or inflamma-
tion that seems to be secondary to the effects of IL6 trans-
signaling on stromal cells [38]. Our studies demonstrate
that IL6/sIL6R shapes the expression program of
leukocyte recruiting factors mediated by TNFα in SF. In
addition, these results confirm that IL6 trans-signaling dir-
ectly enhanced TNFα-induced expression of monocyte-
and lymphocyte-regulating factors such as IL6, CCL2, and
CCL8, while inhibiting the expression of the neutrophil-
recruiting factor IL8/CXCL8. The functional relevance of
these changes in gene expression patterns are highlighted
by the increased MNC migration at the expense of PMN
recruitment upon IL6/sIL6R trans-signaling. Such sce-
nario may be relevant to arthritis, in which neutrophils
may play an essential role in the initiation of RA but
mononuclear leukocytes infiltration would explain chron-
icity [39, 40]. In this context, regulation of the SF inflam-
matory response by IL6/sIL6R would be playing a major
role in the transition to sustained inflammation.
The temporal order of induction and the relative duration
of the various inflammatory events induced by TNFα and
IL6/sIL6R suggests a gene activation program that ensures
a rapid inflammatory response [19–21]. Kinetics and stabil-
ity analyses of gene expression, as well as the differential
Fig. 6 Inhibition of TNFα-induced genes by ruxolitinib in SF. TNFα-induced (10 ng/ml) (a) and IL6/sIL6R-induced (50 ng/ml each) (b) mRNA expression for
24 h in the presence and absence of ruxolitinib (RUXO) (5 μg/ml). Results are mean ± SEM from three to six independent SF cultures (*Wilcoxon test)
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to what is described in other cells types [19], SF display a
pattern of gene expression controlled by both transcrip-
tional and post-transcriptional mechanisms. In contrast, the
fast decay observed in IL6/sIL6R-induced mRNAs suggests
that de novo transcriptional mechanisms are mainly, if not
exclusively, regulating the expression genes induced by IL6/
sIL6R in SF, even for the stable expression of genes such as
CCL8 or MMP1. Furthermore, IL6/sIL6R signaling did not
modify the stability of TNFα-expressed mRNAs, suggesting
an independent transcriptional regulation of commonly in-
duced genes.Evidences suggest that chronic pathological states are
associated with disease-specific stable changes in gene
expression, many of them consistent with epigenetic
mechanisms. It has been shown that TNFα can display a
gene-specific priming effect on RASF, mediated by epi-
genetic changes, that enhances subsequent inflammatory
response to other factors such as IFNs [22]. However,
our data do not demonstrate TNFα priming of gene ex-
pression induced by IL6/sIL6R. Altogether, our results
suggest that the cooperative effect elicited by IL6/sIL6R
in TNFα-responses requires the sustained presence of
both factors, potentially making SF more responsive to
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ing inhibitors.
IL6/sIL6R activation of SF may not only contribute to
synovitis by sustaining leukocyte infiltration within the
inflamed joint, but also enhancing their matrix degrad-
ing activity. Similar to previous investigations, we ob-
served a consistent up-regulation of MMP1 expression
upon IL6/sIL6R stimulation of SF [41]. For most of the
MMPs, TNFα induces activation via several transcription
factors, including NF-kB and activator protein 1 (AP-1)
[42]. In contrast, IL6/sIL6R effect on these genes seems
to be more specific. For instance, MMP1 and MMP3
genes bear STAT binding sites [43] that would make
them susceptible of IL6-induction by promoter-bound
STAT3 or STAT1, in contrast to other MMPs gene pro-
moters that do not have STAT motifs [44]. Although
differences in the cell sources used in both studies may
account for part of the discrepancies between Araki’s re-
sults [41] and ours, the fact that MMP3 is not expressed
at any dose tested, even under active transcriptional con-
ditions such as those imposed by TNFα, suggests that
IL6 does not induce the recruitment of transcription fac-
tors to the MMP3 promoter, further supporting that de
novo transcription has a major role in the response me-
diated by IL6/sIL6R signaling.
Of interest is the IL6/sIL6R inhibitory effect on TNFα-
mediated expression of MMP10. MMP10 is linked to the
control of the resolution phase of inflammation in models
of pulmonary inflammation and experimental colitis, where
MMP10 deficiency exacerbates the disease [18, 45, 46].
Therefore, IL6/sIL6R may also potentiate TNFα inflamma-
tory response by restraining this anti-inflammatory loop.
Conclusions
Although our study mostly rely on mRNA expression ana-
lysis, thus limiting the interpretation of our conclusions at
the pathological level, our findings places SF as a relevant
target for IL6 trans-signaling response that contributes to
leukocyte infiltration and joint destruction through direct ef-
fects and by modulating TNFα actions (Additional file 4: Fig-
ure S3), explaining the local effects of IL6-targeted DMARDs
with independence of their immunoregulatory potential.
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